These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38999429)

  • 1. Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study.
    Galluzzo M; Trovato E; Talamonti M; Caldarola G; Di Nardo L; Lazzeri L; Mugheddu C; Burlando M; Balestri R; Bernardini N; Biondi G; Vellucci L; Russo F; De Simone C; Paganini C; Rech G; Cozzani EC; Atzori L; Montesu MA; Potenza C; Chiricozzi A; Rubegni P
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999429
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study.
    Nguyen HT; Pham NTU; Tran TNA; Pham NN; Bui YT; Vu TTP
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):465-476. PubMed ID: 36472791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
    Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
    Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
    Augustin M; Sator PG; von Kiedrowski R; Conrad C; Rigopoulos D; Romanelli M; Ghislain PD; Torres T; Ioannides D; Aassi M; Schulz B; Jagiello P;
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1796-1804. PubMed ID: 35696305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients with Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp.
    Kyrmanidou E; Kemanetzi C; Stavros C; Trakatelli MG; Patsatsi A; Madia X; Ignatiadi D; Kalloniati E; Apalla Z; Lazaridou E
    Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety.
    Asawanonda P; Pattamadilok B; Chularojanamontri L; Chuamanochan M; Choonhakarn C; Chakkavittumrong P; Sangob N; Rajatanavin N
    Dermatol Ther; 2022 Dec; 35(12):e15958. PubMed ID: 36279306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal.
    Mendes-Bastos P; Morais P; Ferreira P; Loureiro M; Sanganha J; Santiago L; Basto AS; Henrique M
    Dermatol Ther; 2022 Jul; 35(7):e15510. PubMed ID: 35419886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.
    Al-Homood IA; Alajlan M; Alberdisi M; Alturki M; Ahmed AA; Zakaria N
    Adv Rheumatol; 2024 Apr; 64(1):34. PubMed ID: 38685124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
    Megna M; Di Costanzo L; Argenziano G; Balato A; Colasanti P; Cusano F; Galluccio AG; Gambardella A; Lembo S; Mozzillo R; Scotto Di Luzio G; Fabbrocini G; Balato N
    Expert Opin Biol Ther; 2019 Aug; 19(8):855-861. PubMed ID: 31140882
    [No Abstract]   [Full Text] [Related]  

  • 12. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
    Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
    J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study.
    Galica K; Lesiak A; Ciążyńska M; Noweta M; Bednarski I; Narbutt J
    Postepy Dermatol Alergol; 2021 Dec; 38(6):973-978. PubMed ID: 35126003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab Demonstrated High Effectiveness in Vietnamese Patients with Moderate-To-Severe Plaque Psoriasis in a Real-World Clinical Setting: 16 Week Results from an Observational Study.
    Nguyen HT; Pham NTU; Tran TNA; Nguyen NTT; Vu TTP
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1613-1621. PubMed ID: 34275123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.
    Alegre-Sancho JJ; Núñez-Monje V; Campos-Fernández C; Balaguer-Trull I; Robustillo-Villarino M; Aguilar-Zamora M; Garijo-Bufort M; Pedraz-Penalva T; Peña-González C; de la Morena I; Bedoya-Sanchís D; Yankova-Komsalova L; Conesa-Mateos A; Martinez-Cristóbal A; Navarro-Blasco FJ; Senabre-Gallego JM; Sivera F
    Front Med (Lausanne); 2023; 10():1294247. PubMed ID: 38053615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study.
    Ortolan A; Lorenzin M; Leo G; Pampaloni F; Messina F; Doria A; Piaserico S; Ramonda R
    Dermatology; 2022; 238(5):897-903. PubMed ID: 35263743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.
    Dastoli S; Passante M; Loconsole F; Mortato E; Balato A; Piccolo V; Guarneri C; Macca L; Provenzano E; Valenti G; D'Amico D; Micali G; Musumeci ML; Palazzo G; Foti C; Romita P; Fabbrocini G; Megna M; Sammarra I; Bennardo L; Patruno C
    J Dermatolog Treat; 2023 Dec; 34(1):2200868. PubMed ID: 37026590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
    Rompoti N; Sidiropoulou P; Panagakis P; Stratigos A; Papoutsaki M; Stefanaki E; Vavouli C; Politou M; Befon A; Kostakis P; Rigopoulos D; Nicolaidou E
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1240-1247. PubMed ID: 31953892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience.
    Mastorino L; Dapavo P; Cariti C; Susca S; Siliquini N; Ortoncelli M; Stroppiana E; Verrone A; Giunipero di Corteranzo I; Leo F; Quaglino P; Ribero S
    J Pers Med; 2024 Jul; 14(7):. PubMed ID: 39063973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
    Warren RB; Barker JNWB; Finlay AY; Burden AD; Kirby B; Armendariz Y; Williams R; Hatchard C; Khare S; Griffiths CEM
    Br J Dermatol; 2020 Jul; 183(1):60-70. PubMed ID: 31628677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.